ProCE Banner Activity

Rates of Invasive Pneumococcal Disease in Adults With HIV in the Era of 13-Valent Pneumococcal Conjugate Vaccine, 2008-2018

Slideset Download
Conference Coverage
Active surveillance demonstrates that introduction of PCV13 led to declines in IPD in people with and without HIV and suggests benefits of newly approved higher valency PCVs.

Released: October 07, 2021

Expiration: October 06, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Ferring Pharmaceuticals, Inc.

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

Merck Sharp & Dohme Corp.

ViiV Healthcare